Sign in

You're signed outSign in or to get full access.

David Foy

About David Foy

David Foy, 58, is an independent director of Bowhead Specialty Holdings Inc. (BOW) and has served on the board since May 2024. He is a seasoned insurance executive and actuary: former EVP & CFO of White Mountains Insurance Group (2003–2017), an independent insurance consultant (2017–2021), and currently a senior advisor to Bain Capital Insurance (since Oct 2021). He previously served on the board of managers of BGP (Sept 2022–Dec 2024), and is a director of Federal Life Insurance Company and Enhance Health. He holds a B.S. in Applied Statistics from Rochester Institute of Technology and is a Fellow of the Society of Actuaries .

Past Roles

OrganizationRoleTenureCommittees/Impact
White Mountains Insurance GroupEVP & CFOMar 2003 – May 2017Led finance, reporting, capital; deep P&C industry expertise
Insurance Industry (independent consultant)ConsultantMay 2017 – Oct 2021Advisory work across insurers
Bain Capital InsuranceSenior AdvisorOct 2021 – presentStrategic advisory within insurance; capital and operations
BGP (Board of Managers)MemberSept 2022 – Dec 2024Governance for pre-IPO structure

External Roles

OrganizationRoleTenureNotes
Federal Life Insurance CompanyDirectorNot specifiedCurrent public company directorship
Enhance HealthDirectorNot specifiedCurrent board service

Board Governance

  • Board class and tenure: Foy is a Class II director; term expires at the 2026 annual meeting .
  • Independence: Board determined David Foy is “independent” under NYSE listing standards .
  • Committee assignments:
    • Audit Committee: Chair; designated “audit committee financial expert” under Item 407(d)(5) of Regulation S-K; Audit Committee held two meetings in FY2024 .
    • Compensation, Nominating & Corporate Governance (CNCG) Committee: Member; committee held one meeting in FY2024 .
  • Attendance: Board held two meetings in FY2024; each incumbent director attended at least 75% of aggregate board/committee meetings for which they served .
  • Board leadership: Chair is Matthew Botein; CEO is Stephen Sills; policy favors separation of roles or having a lead independent director .

Fixed Compensation (Director Pay – FY2024)

ComponentAmountNotes
Annual Director Package (cash)$80,000 Under NED policy, directors may elect $80,000 cash + $80,000 RSUs or $160,000 RSUs
Annual Director Package (RSUs grant-date value)$79,985 Foy elected mixed package; RSUs vest at earlier of one year from grant or next AGM; holding required during service
Audit Committee Chair Retainer (cash)$50,000 Additional cash retainer for Audit Chair
Total FY2024 Compensation$209,985 $130,000 cash + $79,985 stock awards

Directors nominated by AFMIC or GPC Fund and employees are ineligible for director compensation; Foy is not an AFMIC/GPC nominee .

Performance Compensation

ProgramMetricTarget StructureApplicability to Foy
Director equityTime-based RSUsVest at earlier of one year or next AGM; holding required during service Applicable (no performance metrics)
Stock optionsN/ACompany does not grant stock options at this time Not applicable
Executive PSUsStock price CAGR thresholds (15%/20%/25% for 75%/100%/125% payout) Executive-only; CEO PSUsNot applicable to director compensation

No director-specific performance metrics (TSR/EBITDA/ESG) were disclosed for Foy’s compensation .

Other Directorships & Interlocks

EntityRelationship to BOWPotential Interlock / Notes
AFMIC; GPC FundShareholder nominee rights per agreements Current nominees: AFMIC—Troy Van Beek, David Holman; GPC—Matt Botein, Zhak Cohen; Foy is independent, not a nominee of these investors
Federal Life Insurance CompanyExternal boardNo related-party transaction disclosed with BOW
Enhance HealthExternal boardNo related-party transaction disclosed with BOW

Expertise & Qualifications

  • Fellow of the Society of Actuaries; B.S. in Applied Statistics (RIT) .
  • Audit committee financial expert designation; extensive insurance finance leadership (White Mountains CFO) .
  • Broad strategic and capital advisory experience (Bain Capital Insurance senior advisor) .

Equity Ownership

HolderShares Beneficially Owned% of OutstandingRSUs Outstanding (12/31/2024)
David Foy<1% 4,705
  • Section 16 compliance: All directors complied in FY2024 except two Form 3 omissions by others (Fondriest, Sills) later corrected; no issues cited for Foy .
  • Hedging/pledging: Company policy prohibits hedging, margining, and pledging by directors .

Governance Assessment

  • Strengths

    • Independent director with deep insurance finance and actuarial credentials; designated audit committee financial expert, signaling credible oversight of reporting, controls, and auditor independence .
    • Chairs Audit Committee; committee charter includes approving related-party transactions and overseeing risk—key guardrails for a company with significant investor affiliates .
    • Pay structure aligned with shareholder exposure via RSUs that vest at AGM and must be held during service; limited cash retainer beyond standard and role-based chair fee .
  • Watch Items / Potential Red Flags

    • Compensation committee independence in transition: the company ceased “controlled company” status in Oct 2024 and is phasing into NYSE independence requirements; current CNCG chair is Matthew Botein (GPC nominee), indicating investor influence until full compliance is reached .
    • Investor nomination rights: AFMIC and GPC Fund retain rights to nominate directors subject to thresholds, which can shape board composition; while Foy is independent, overall board balance should be monitored for independence and committee composition impacts .
  • Engagement/Attendance

    • Board met twice in FY2024; Audit Committee met twice; CNCG met once; all incumbents met the 75% attendance threshold—no attendance concerns noted for Foy .
  • Related-Party Exposure

    • Audit Committee (chaired by Foy) is responsible for pre-approvals and related-party transaction oversight; no Foy-specific related-party transactions disclosed .

Overall, Foy brings strong financial oversight and actuarial expertise as Audit Chair, supporting investor confidence in reporting integrity. Monitoring CNCG independence and investor nominee influence remains important until NYSE independence phase-in is complete .